Calidi Biotherapeutics, Inc. $CLDI Shares Sold by Bank of Montreal Can

Bank of Montreal Can trimmed its position in shares of Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) by 13.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 422,500 shares of the company’s stock after selling 67,300 shares during the period. Bank of Montreal Can owned approximately 1.16% of Calidi Biotherapeutics worth $97,000 as of its most recent SEC filing.

Separately, Belpointe Asset Management LLC purchased a new position in shares of Calidi Biotherapeutics in the 1st quarter worth about $141,000. 12.53% of the stock is owned by hedge funds and other institutional investors.

Calidi Biotherapeutics Trading Down 0.7%

Shares of NYSEAMERICAN:CLDI opened at $1.37 on Friday. The stock has a 50-day simple moving average of $1.54 and a 200-day simple moving average of $3.52. Calidi Biotherapeutics, Inc. has a 1 year low of $1.10 and a 1 year high of $27.63. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.11.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($2.21) earnings per share for the quarter. As a group, sell-side analysts forecast that Calidi Biotherapeutics, Inc. will post -4.48 EPS for the current year.

Calidi Biotherapeutics Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.